PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2015 | 5 | 3 | A133-138
Article title

Advanced skin melanoma – systemic treatment

Content
Title variants
Languages of publication
EN
Abstracts
EN
In Poland, morbidity and mortality rates for melanoma are constantly increasing. In the case of inoperable disease or distant metastases, prognosis remains poor. For many years, dacarbazine has been the gold standard in systemic treatment. Recently, a significant progress in melanoma therapy has been observed. Introducing targeted therapy or immunotherapy significantly improved treatment outcomes. This review paper presents current knowledge on systemic treatment of advanced melanoma, including treatment availability in Poland.
Keywords
Discipline
Publisher

Journal
Year
Volume
5
Issue
3
Pages
A133-138
Physical description
Contributors
  • Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Poland, m_kruczala@onet.pl
author
  • Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Poland
  • Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Poland
author
  • Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Poland
References
  • 1. [online: http://onkologia.org.pl/czerniak-skory-c43/].
  • 2. Wojciechowska U, Ditkowska J. Poprawa przeżyć chorych na nowotwory złośliwe w Polsce. Analiza przeżyć pacjentów zdiagnozowanych w latach 2003–2005. Nowotwory. J Oncol 2013; 63: 279-285.
  • 3. Świtaj T, Falkowski S, Rutkowski P et al. Systemowe leczenie rozsianego czerniaka. In: Złośliwe nowotwory skóry. Rutkowski P (eds). Via Medica, Gdańsk 2014: 135-137.
  • 4. Eigentler TK, Caroli UM, Radny P et al. Palliative therapy of disseminated malignant melanoma: a systemic reviews of 41 randomized trials. Lancet Oncol 2003; 4: 748-759.
  • 5. Woodman SE, Lazar AL, Aldape KD, Davies MA. New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res 2012; 18: 1195-1200.
  • 6. Long GV, Menzies AM, Nagrial AM et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-1246.
  • 7. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
  • 8. [online: http://www.roche-trials.com/studyResultGet.action?studyResultNumber=MO25653].
  • 9. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
  • 10. Kwapisz D, Rutkowski P. Nowe możliwości leczenia chorych na uogólnione czerniaki skóry. Przegl Dermatol 2014; 101: 20-26.
  • 11. Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
  • 12. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367(18): 1694-1703.
  • 13. Robert C. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Abstract #3301. 18th ECCO – 40th ESMO European Cancer Congress, September 2015, Vienna, Austria.
  • 14. Corthay A. Does the immune system naturally protect against cancer? Front Immunol 2014; 5: 197.
  • 15. Dunn GP, Bruce AT, Ikeda H et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3(11): 991-998.
  • 16. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736.
  • 17. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
  • 18. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
  • 19. Lebbe C, Weber JS, Maio M et al. Five-year survival rates for patients (pts) with metastatic melanoma (MM) treated with ipilimumab (IPI) in phase II trials. Ann Oncol 2012; 23(supl. 9): 363-364.
  • 20. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
  • 21. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
  • 22. Topalian SL, Sznol M, McDermott DF. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32(10): 1020-1030.
  • 23. Ribas A, Hodi FS, Kefford R et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol 2014; 32: 5s (supl.abstr. LBA9000).
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-01786700-49d4-4bd8-aaa2-e1b0a1ba6bee
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.